Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Biochemical Pharmacology|February 11, 1999
Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformateE Tramontano, G Piras, J W Mellors, et al.Antimicrobial Agents and Chemotherapy|June 20, 2000
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineH Z Bazmi, J L Hammond, S C Cavalcanti, et al.Antimicrobial Agents and Chemotherapy|May 1, 1995
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesJ W Mellors, H Z Bazmi, R F Schinazi, et al.Antimicrobial Agents and Chemotherapy|April 1, 1993
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosidesR F Schinazi, R M Lloyd, M H Nguyen, et al.Molecular Pharmacology|January 1, 1993
A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150)J W Mellors, G J Im, E Tramontano, et al.Antimicrobial Agents and Chemotherapy|May 17, 2001
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceJ L Hammond, D L Koontz, H Z Bazmi, et al.Pageof 1